re.Mind Capital — 2021 Investments
3 investments dated 2021 · listed companies and verified rows first · show all
Delix Therapeutics develops third-generation, non-hallucinogenic neuroplastogens for people with neurological conditions, using a discovery platform to identify novel compounds.
BiotechDigital HealthMedical Devices
Co-investorsArtis VenturesCasa Verde CapitalNoeticOMX VenturesPsyMed VenturesRA Capital+6 more
Active seed-stage healthcare company
Eugene, US
Nicholas Allen(Chief Executive Officer)Phillip Scripa(Chief Financial Officer and Secretary)William Shortt(Chief Operating Officer)Jan Hardorp(Director)
Co-investorsBIP VenturesJLS
Synchron develops brain-computer interface technology delivered via catheter to restore or improve motor and cognitive function in people with impairment or decline.
BiotechDeep TechMedical DevicesCampbell, US
Thomas James Oxley(Executive Officer, Director)Nicholas Opie(Director)inThomas Oxley(Founder)in
BoardRahul Sharma(Director)Alex Morgan(Director)inMartin Dieck(Director)
Co-investorsARCH Venture PartnersForepont Capital PartnersID8 InvestmentsKaleida CapitalKhosla VenturesBezos Expeditions+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.